Damora Therapeutics, Inc. Common Stock (DMRA)

Price$27.00

Favorite Metrics

Price vs S&P 500 (4W)19.99%

Market Capitalization$1.60B

All Metrics

Cash Flow / Share (Quarterly)$-4.21

Price vs S&P 500 (YTD)0.95%

EPS (TTM)$-142.48

10-Day Avg Trading Volume0.24M

EPS Excl Extra (TTM)$-142.48

EPS (Annual)$-153.95

ROI (Annual)-87.29%

Cash / Share (Quarterly)$161.29

ROA (Last FY)-80.54%

EBITD / Share (TTM)$-154.70

ROE (5Y Avg)-97.04%

Cash Flow / Share (Annual)$-4.21

P/B Ratio6.68x

Net Income / Employee (Annual)$-42

Net Interest Coverage (TTM)-145.71x

ROA (TTM)-279.49%

EPS Incl Extra (Annual)$-153.95

Current Ratio (Annual)12.98x

Quick Ratio (Quarterly)12.91x

3-Month Avg Trading Volume0.29M

Revenue / Employee (TTM)$0

52-Week High$29.22

EPS Excl Extra (Annual)$-153.95

Quick Ratio (Annual)12.91x

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)12.98x

Revenue / Employee (Annual)$0

Cash / Share (Annual)$161.29

Net Income / Employee (TTM)$-42

ROE (Last FY)-87.29%

Net Interest Coverage (Annual)-151.27x

EPS Basic Excl Extra (Annual)$-153.95

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-142.48

Receivables Turnover (Annual)0.00x

ROI (TTM)-307.40%

Revenue / Share (Annual)$0.00

Year-to-Date Return4.31%

5-Day Price Return-0.30%

EPS Normalized (Annual)$-153.95

ROA (5Y Avg)-86.51%

Month-to-Date Return2.74%

EBITD / Share (Annual)$-154.69

ROI (5Y Avg)-97.04%

EPS Basic Excl Extra (TTM)$-142.48

Beta-3.42x

Revenue / Share (TTM)$0.00

ROE (TTM)-307.40%

52-Week Low$16.50

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.29

4.38

4.30

4.27

About

Damora Therapeutics develops biologics for calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant unmet medical need for disease-modifying treatments. The company's pipeline includes DMR-001, DMR-002, DMR-003, and GB3226, designed to provide broad mutation coverage in hematologic disorders.